Back to search results

Peer Navigation for Metastatic Prostate Cancer Genetic Evaluation

This study is looking at whether a trained peer navigator can help African American men with metastatic prostate cancer (cancer that has spread) better understand and go through genetic testing. Genetic testing is important for making treatment decisions. The study compares receiving help from a peer navigator with receiving standard care. Researchers want to see if peer navigation increases how often men engage with genetic counseling. You may be able to join if you are an African American man, 18 or older, speak English, and have metastatic prostate cancer.

Study design
This is an interventional study with 120 planned participants. Participants will be randomly assigned to either receive peer navigation services or standard care.
What's involved
If you join, you will either receive assistance from a peer navigator or standard care during your genetic evaluation process. This includes genetic counseling, genetic testing, and receiving your results.
Compensation
Not stated in the trial record.
Follow-up
The study will measure engagement with genetic counseling for up to 4 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05487846

Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation

Recruiting
NAAges 18+InterventionalHealth services
Thomas Jefferson University
~120 participants
Updated 2026-04-14 on ClinicalTrials.gov
What's tested:Patient NavigationGenetic CounselingSurvey AdministrationBest Practice

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Frequency of pretest genetic counseling engagement
Measured over Up to 4 years

Conditions

Metastatic Prostate Carcinoma
Stage III Prostate Cancer AJCC v8
Stage IV Prostate Cancer AJCC v8

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Amy Leader, DrPH, MPH · PRINCIPAL_INVESTIGATOR · Thomas Jefferson University

Who to contact

Amy Leader, DrPH, MPH
[email protected]
215-955-7739
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provide signed and dated informed consent form
English speaking only
Willing to comply with all study procedures and be available for the duration of the study
Any individual \>= 18 years old
African American men who meet National Comprehensive Cancer Network (NCCN) criteria for testing will be offered participation. These criteria include any one of the following: (1) metastatic prostate cancer (PCA); (2) intraductal or ductal pathology; (3) T3a or higher; (4) grade group 4 or Gleason 8 or higher; (5) family history of breast, ovarian, prostate, pancreatic, colorectal, or uterine cancers in 3 or more blood relatives particularly if diagnosed at age \< 50. These criteria have been adapted from the NCCN Prostate Cancer (version 2.2021) and NCCN Breast, Ovarian, and Pancreatic (version 2.2021) guideline
Anyone who has trouble understanding the consent or with significant anxiety detected during the consent process will also be excluded

What this trial measures

  • Frequency of pretest genetic counseling engagementUp to 4 years

    Compared between randomized study groups. Tested using a chi-square test. Summarized between study groups in tables with descriptive statistics (e.g.'s, means and standard deviations if continuous, frequencies and percentages if discrete) with 95% confidence intervals and also graphically in data plots at each time they are assessed along with changes in responses over time.